Fundraising FoxCyteSi
Menlo Park, US · Founded 2018 · 1 known investors
Find your way into CyteSi
Sign up to see every warm intro you have to CyteSi
- Paths you didn't know you had: your email and LinkedIn already hold routes to the CyteSi team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
CyteSi builds a semiconductor-based Bio Processing Unit (BPU) that creates a software-defined wet lab, using a programmable continuous-flow system to automate liquid-handling workflows such as NGS library prep, drug discovery, and reagent synthesis. The platform is aimed at labs and AI-driven research teams seeking high-throughput physical validation with reduced reagent use.
Founders & leadership
PH
Peng HuNamed on SEC filing
XC
Xi ChenNamed on SEC filing
WH
Wing Hung WongNamed on SEC filing
TW
Tung-Yu WuNamed on SEC filing
Investors · 1
-2.png)
Reported raises · per SEC filings
Form D private placements$12.4M disclosed across 2 rounds · 2022–2024
▶$5.5MraisedMay 2024 · 6 investors · Other TechnologyRule 506(b)
▶$5.5MraisedMay 2024 · 6 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Wing Hung WongDirector
- Tung-Yu WuExecutive Officer, Director
- Xi ChenExecutive Officer
- Peng HuDirector
- Offering amount
- $6.5M
- Amount sold
- $5.5M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.9MraisedJun 2022 · 8 investors · Other TechnologyRule 506(b)
▶$6.9MraisedJun 2022 · 8 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Peng HuDirector
- Xi ChenExecutive Officer
- Wing Hung WongDirector
- Tung-Yu WuDirector
- Offering amount
- $6.9M
- Amount sold
- $6.9M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does CyteSi do?
- CyteSi builds a semiconductor-based Bio Processing Unit (BPU) that creates a software-defined wet lab, using a programmable continuous-flow system to automate liquid-handling workflows such as NGS library prep, drug discovery, and reagent synthesis. The platform is aimed at labs and AI-driven research teams seeking high-throughput physical validation with reduced reagent use.
- Who are CyteSi's investors?
- CyteSi's investors include Amino Capital.
- How much funding has CyteSi raised?
- CyteSi has disclosed $12.4M raised across 2 rounds.
- Where is CyteSi headquartered?
- CyteSi is headquartered in Menlo Park, US.